A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
- Home |
- ADA: Boehringer execs claim survodutide tolerability ‘consistent’ with class despite phase 3 update
ADA: Boehringer execs claim survodutide tolerability ‘consistent’ with class despite phase 3 update
- June 7, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
